Buprenorphine Enhanced Taper Tolerability Evaluation Report (BETTER): A Case Series.
Claudia EplandHaley PalsJohn HaydenPublished in: Substance use & addiction journal (2024)
Findings from these cases support current evidence-based guidance that ER-BUP tapering is better tolerated than traditional SL-BUP tapering. These patient cases and pharmacokinetic modeling of ER-BUP suggest that a target preinjection dose of 2 to 6 mg SL-BUP will minimize the risk of more severe adverse effects or withdrawal symptoms. Patients and providers should ensure that remission is well-established before initiating SL-BUP taper. A shared decision-making approach can help support patient autonomy and understanding safety risks of discontinuing SL-BUP. Future prospective studies with larger populations could further refine dosing strategies with various SL-BUP preinjection doses and newer ER-BUP formulations.
Keyphrases
- end stage renal disease
- case report
- ejection fraction
- estrogen receptor
- chronic kidney disease
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- clinical trial
- early onset
- rheumatoid arthritis
- climate change
- risk assessment
- systemic lupus erythematosus
- ulcerative colitis
- depressive symptoms
- patient reported outcomes
- human health